Business Description
Exicure Inc
NAICS : 325411
SIC : 2834
ISIN : US30205M3097
Total Employee Number:
8Description
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 118.36 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 20.1 | |||||
3-Year FCF Growth Rate | 67.2 | |||||
3-Year Book Growth Rate | -65.5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 16.61 | |||||
9-Day RSI | 25.72 | |||||
14-Day RSI | 30.25 | |||||
3-1 Month Momentum % | -25.78 | |||||
6-1 Month Momentum % | -44.27 | |||||
12-1 Month Momentum % | -47.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.79 | |||||
Quick Ratio | 0.79 | |||||
Cash Ratio | 0.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -85.8 | |||||
Shareholder Yield % | 38.93 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -147.37 | |||||
ROA % | -60.04 | |||||
ROIC % | -82.41 | |||||
3-Year ROIIC % | 169 | |||||
ROC (Joel Greenblatt) % | -1606.28 | |||||
ROCE % | -80.93 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.81 | |||||
EV-to-EBIT | -0.96 | |||||
EV-to-EBITDA | -1 | |||||
EV-to-Forward-Revenue | 0.68 | |||||
EV-to-FCF | -1.18 | |||||
Price-to-GF-Value | 3.54 | |||||
Earnings Yield (Greenblatt) % | -104.17 | |||||
FCF Yield % | -66.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XCUR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exicure Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.55 | ||
| Beta | 7.231 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 3.32 | ||
| Volatility % | 65.78 | ||
| 14-Day RSI | 30.25 | ||
| 14-Day ATR ($) | 0.346185 | ||
| 20-Day SMA ($) | 2.5375 | ||
| 12-1 Month Momentum % | -47.82 | ||
| 52-Week Range ($) | 1.71 - 9.5 | ||
| Shares Outstanding (Mil) | 6.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exicure Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exicure Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-06 17:00 | In 124 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 32 days | ||
| First quarter earnings results for 2026 | 2026-05-29 | 2.97 (+6.07%) | ||
| Annual report for 2025 | 2026-03-25 | 4.47 (+0.22%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 4.25 (+3.66%) | ||
| General meeting for 2025 | 2025-11-06 17:00 | 4.10 (-3.53%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 7.36 (-3.16%) | ||
| First quarter earnings results for 2025 | 2025-06-27 | 5.55 (-6.02%) | ||
| Annual report for 2024 | 2025-03-18 | 12.99 (-1.74%) |
Show
Entries
Exicure Inc Frequently Asked Questions
What is Exicure Inc(XCUR)'s stock price today?
The current price of XCUR is $1.91. The 52 week high of XCUR is $9.50 and 52 week low is $1.71.
When is next earnings date of Exicure Inc(XCUR)?
The next earnings date of Exicure Inc(XCUR) is 2026-08-07 Est..
Does Exicure Inc(XCUR) pay dividends? If so, how much?
Exicure Inc(XCUR) does not pay dividend.
Guru Commentaries on NAS:XCUR
No articles.
Press Release
Articles on Exicure Inc
No articles.
Headlines
See More- 1
Jun 10, 2026
Exicure receives Nasdaq notice over stockholders' equity requirement
Seeking Alpha • 3:09pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers